Small-cap biotech stocks — shares of companies with a market value of $500 million or less — can be lucrative for investors. They can also be hard to navigate. Check out a semi-regular column from STAT senior biotech writer Adam Feuerstein on the ups and downs of these companies if you’re interested in learning more.
In his latest column, Adam takes a look at ResTORbio (TORC), Trovagene (TROV), and Atossa Genetics (ATOS). His take: healthy skepticism at best. Full-tilt “GET OFF MY LAWN!” at worst. You can read the full story here to see why.
And, in case you missed them, don’t forget to check out his previous small-cap columns, as well:
Subscribe
|
